Atai life sciences and introspect digital therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression

Berlin and san diego, sept. 09, 2021 (globe newswire) -- atai life sciences  (nasdaq: atai) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform introspect digital therapeutics, inc. (“introspect”), today announced a usability study of introspect's digital therapeutic (dtx) app technology in support of standard of care ketamine therapy for patients with treatment resistant depression (trd) in collaboration with kadima neuropsychiatry. trd impacts 100 million people globally, close to a third of the 300 million diagnosed with depression, many of whom are geographically restricted in their ability to access in-person psychological care.
ATAI Ratings Summary
ATAI Quant Ranking